Medical Dosimetry
Volume 36, Issue 3 , Pages 231-239 , Autumn 2011

Postoperative Intensity Modulated Radiation Therapy in High Risk Prostate Cancer: A Dosimetric Comparison

  • Cinzia Digesú, M.D.

      Affiliations

    • Department of Radiotherapy, “John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso
    • ,
  • Savino Cilla, M.P.

      Affiliations

    • Department of Medical Physics, “John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso
    • ,
  • Andrea De Gaetano, M.D.

      Affiliations

    • CNR–Institute of Systems Analysis and Computer Science (IASI), BioMathLab, Rome
    • ,
  • Mariangela Massaccesi, M.D.

      Affiliations

    • Department of Radiotherapy, “John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso
    • ,
  • Gabriella Macchia, M.D.

      Affiliations

    • Department of Radiotherapy, “John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso
    • Corresponding Author InformationReprint requests to: Gabriella Macchia, M.D., UO Radioterapia, Centro di Ricerca e Formazione ad Alta Tecnologia nelle Scienze Biomediche “Giovanni Paolo II”, Largo A. Gemelli 1, 86100 Campobasso, Italy
    • ,
  • Edy Ippolito, M.D.

      Affiliations

    • Department of Radiotherapy, “John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso
    • ,
  • Francesco Deodato, M.D.

      Affiliations

    • Department of Radiotherapy, “John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso
    • ,
  • Simona Panunzi, M.S.

      Affiliations

    • CNR–Institute of Systems Analysis and Computer Science (IASI), BioMathLab, Rome
    • ,
  • Chiara Iapalucci, R.T.

      Affiliations

    • Department of Radiotherapy, “John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso
    • ,
  • Gian Carlo Mattiucci, M.D.

      Affiliations

    • Department of Radiotherapy, Policlinico Universitario “A. Gemelli,” Catholic University, Rome
    • ,
  • Elisa D'Angelo, M.D.

      Affiliations

    • Department of Radiotherapy, “John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso
    • ,
  • Gilbert D.A. Padula, M.D.

      Affiliations

    • Department of Radiation Oncology, The Lacks Cancer Center, Saint Mary's Health Care, Grand Rapids, MI
    • ,
  • Vincenzo Valentini, M.D.

      Affiliations

    • Department of Radiotherapy, Policlinico Universitario “A. Gemelli,” Catholic University, Rome
    • ,
  • Numa Cellini, M.D.

      Affiliations

    • Department of Radiotherapy, Policlinico Universitario “A. Gemelli,” Catholic University, Rome
    • ,
  • Angelo Piermattei, M.P.

      Affiliations

    • Department of Medical Physics, “John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso
    • ,
  • Alessio G. Morganti, M.D.

      Affiliations

    • Department of Radiotherapy, “John Paul II” Center for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso

Received 5 May 2009 ,Accepted 24 March 2010.

References 

  1. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA. 2006;296:2329–2335
  2. Bolla M, van Poppel H, Collette L, et al. European Organization for Research and Treatment of Cancer Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572–578
  3. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol. 2009;27:2924–2930
  4. Valicenti RK, Gomella LG, Ismail M, et al. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: The importance of radiation dose. Urology. 1998;52:1034–1040
  5. Cozzarini C, Montorsi F, Fiorino C, et al. Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: A single-institution analysis of 334 high-risk, node-negative patients. Int. J. Radiat. Oncol. Biol. Phys. 2009;75:966–974
  6. Mendenhall WM, Henderson RH, Nichols RC, et al. Postprostatectomy radiotherapy for prostate cancer. Am. J. Clin. Oncol. 2009;(Epub ahead of print)
  7. Alongi F, Fiorino C, Cozzarini C, et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother. Oncol. 2009;93:207–212
  8. Roach M, DeSilvio M, Lawton C, et al. Radiation Therapy Oncology Group 9413 Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neo-adjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J. Clin. Oncol. 2003;21:1904–1911
  9. Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: Improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int. J. Radiat. Oncol. Biol. Phys. 2007;69:54–61
  10. Abramowitz MC, Pollack A. Postprostatectomy radiation therapy for prostate cancer. Semin. Radiat. Oncol. 2008;18:15–22
  11. Ling CC, Burman C, Chui CS, et al. Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int. J. Radiat. Oncol. Biol. Phys. 1996;35:721–730
  12. De Meerleer GO, Vakaet LA, De Gersem WR, et al. Radiotherapy of prostate cancer with or without intensity modulated beams: A planning comparison. Int. J. Radiat. Oncol. Biol. Phys. 2000;47:639–648
  13. Jani AB, Su A, Correa D, et al. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity modulated versus conventional radiotherapy using localized fields. Prostate. Cancer. Prostatic. Dis. 2006;10:82–86
  14. De Meerleer GO, Fonteyne VH, Vakaet L, et al. Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control. Radiother. Oncol. 2007;82:160–166
  15. Teh BS, Mai WY, Uhl BM, et al. Intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: Acute toxicity and dose-volume analysis. Int. J. Radiat. Oncol. Biol. Phys. 2001;49:705–712
  16. Vora SA, Wong WW, Schild SE, et al. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007;68:1053–1058
  17. Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int. J. Radiat. Oncol. Biol. Phys. 2007;68:1424–1430
  18. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J. Urol. 2006;176:1415–1419
  19. Cahlon O, Zelefsky MJ, Shippy A, et al. Intensity modulated radiation therapy to a dose of 86.4 Gy for localized prostate cancer: Toxicity data and preliminary biochemical outcomes. Int. J. Radiat. Oncol. Biol. Phys. 2006;66:S33
  20. Cahlon O, Hunt M, Zelefsky MJ. Intensity-modulated radiation therapy: Supportive data for prostate cancer. Semin. Radiat. Oncol. 2008;18:48–57
  21. Bastasch MD, Teh BS, Mai WY, et al. Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: Effect on erectile function. Int. J. Radiat. Oncol. Biol. Phys. 2002;54:101–106
  22. Pinkawa M, Siluschek J, Gagel B, et al. Postoperative radiotherapy for prostate cancer: Evaluation of target motion and treatment techniques (intensity-modulated versus conformal radiotherapy). Strahlenther. Onkol. 2007;183:23–29
  23. Koontz BF, Das S, Temple K, et al. Dosimetric and radiobiologic comparison of 3D conformal versus intensity modulated planning techniques for prostate bed radiotherapy. Med. Dosim. 2009;34:256–260
  24. Arcangeli S, Saracino B, Petrongari MG, et al. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiother. Oncol. 2007;84:148–155
  25. Cozzarini C, Fiorino C, Di Muzio N, et al. Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer. Radiother. Oncol. 2007;84:164–170
  26. Teh BS, Bastasch MD, Mai WY, et al. Preliminary report of the effect of high-dose adjuvant intensity modulated radiation therapy on the sural nerve graft for cavernosal nerve sacrifice after radical prostatectomy. Am. J. Clin. Oncol. 2007;30:395–400
  27. Nath SK, Sandhu AP, Rose BS, et al. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009;(Epub ahead of print)
  28. Sanguineti G, Castellone P, Foppiano F, et al. Anatomic variations due to radical prostatectomy (Impact on target volume definition and dose-volume parameters of rectum and bladder). Strahlenther. Onkol. 2004;180:563–572
  29. Armitage P, Berry G. Statistical Methods in Medical Research. Oxford: Blackwell Scientific Publication Limited; 1994;
  30. Sidhom MA, Kneebone AB, Lehman M, et al. Post-prostatectomy radiation therapy: Consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother. Oncol. 2008;88:10–19
  31. Wu Q, Mohan R, Morris M, et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas (I: Dosimetric results). Int. J. Radiat. Oncol. Biol. Phys. 2003;56:573–585
  32. Mangar SA, Huddart RA, Parker CC, et al. Technological advances in radiotherapy for the treatment of localized prostate cancer. Eur. J. Cancer. 2005;41:908–921
  33. Niemierko A. A generalized concept of equivalent uniform dose (EUD). Med. Phys. 1999;26:1100
  34. Burman C, Kutcher GJ, Emami B, et al. Fitting of normal tissue tolerance data to an analytic function. Int. J. Radiat. Oncol. Biol. Phys. 1991;21:123–135
  35. Muren LP, Wasbø E, Helle SI, et al. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: Planning procedures and early experiences. Int. J. Radiat. Oncol. Biol. Phys. 2008;71:1034–1041
  36. Nutting CM, Convery DJ, Cosgrove VP, et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2000;48:649–656
  37. Liu YM, Shiau CY, Lee ML, et al. The role and strategy of IMRT in radiotherapy of pelvic tumors: Dose escalation and critical organ sparing in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007;67:1113–1123
  38. Li XA, Wang JZ, Jursinic PA, et al. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005;61:1251–1257

PII: S0958-3947(10)00036-1

doi: 10.1016/j.meddos.2010.03.009

Medical Dosimetry
Volume 36, Issue 3 , Pages 231-239 , Autumn 2011

Article Tools

* Image Usage & Resolution